Ultrasound Liver Fat and Heart Scans to Track Heart Health in Fatty Liver Disease
Checks liver fat and heart function with scans in adults with fatty liver disease.
Plain-language title generated from the registry record
Registry title: Integrated Ultrasound-Derived Fat Fraction and 2D/4D HeartAI for Cardiovascular Risk Management in Patients With MASLD
Key facts
- Where
- Guangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 with fatty liver disease (MASLD) who also have at least one heart and metabolism risk factor.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- MASLD (fatty liver disease linked to metabolic problems), diagnosed by imaging or biopsy.
Main reasons for not taking part
- Heavy alcohol use: more than 20 g/day for women or more than 30 g/day for men
- Other causes of fatty liver, such as viral hepatitis or autoimmune liver disease
- Known advanced heart failure (NYHA class III-IV)
- A heart or blood vessel event in the last 6 months
- Pregnancy
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07545343, who can take part
Where in China
- The First Affiliated Hospital, Sun Yat-sen UniversityGuangzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- First Affiliated Hospital, Sun Yat-Sen University
- Trial code
- NCT07545343
- Record updated
- 22 April 2026
- Original description
This prospective observational cohort study aims to evaluate the association between liver fat fraction measured by ultrasound-derived fat fraction (UDFF) and cardiac functional parameters assessed by 2D and 4D HeartAI in adult patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Participants will undergo baseline assessment and repeat evaluations at 6, 12, and 36 months. The study will assess the diagnostic performance of integrated UDFF-HeartAI analysis for detecting subclinical cardiac abnormalities and identify predictors of cardiovascular risk progression and major adverse cardiovascular events in patients with MASLD.Read full original descriptionShow less
Integration of Ultrasound-Derived Fat Fraction With 2D and 4D HeartAI for Cardiovascular Risk Management in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Observational Cohort Study
This prospective observational cohort study aims to evaluate the association between liver fat fraction measured by ultrasound-derived fat fraction (UDFF) and cardiac functional parameters assessed by 2D and 4D HeartAI in adult patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Participants will undergo baseline assessment and repeat evaluations at 6, 12, and 36 months. The study will assess the diagnostic performance of integrated UDFF-HeartAI analysis for detecting subclinical cardiac abnormalities and identify predictors of cardiovascular risk progression and major adverse cardiovascular events in patients with MASLD.
Inclusion: Adults aged 18 to 75 years; Diagnosis of MASLD based on imaging or biopsy; Presence of at least one cardiometabolic risk factor, such as BMI ≥25 kg/m², type 2 diabetes mellitus, or dyslipidemia; No contraindication to ultrasound imaging.
Exclusion: Significant alcohol consumption: >20 g/day for women or >30 g/day for men Secondary causes of hepatic steatosis, such as viral hepatitis or autoimmune liver disease; Known advanced heart failure (New York Heart Association class III-IV); Recent cardiovascular event within 6 months; Pregnancy; Inability to complete follow-up.